Silexion Therapeutics (SLXN) Competitors $0.32 -0.01 (-3.03%) (As of 11/21/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsOwnershipSEC FilingsTrends SLXN vs. IKT, INAB, AIM, PMCB, NKGN, TSBX, SNTI, EVAX, COEP, and BCLIShould you be buying Silexion Therapeutics stock or one of its competitors? The main competitors of Silexion Therapeutics include Inhibikase Therapeutics (IKT), IN8bio (INAB), AIM ImmunoTech (AIM), PharmaCyte Biotech (PMCB), NKGen Biotech (NKGN), Turnstone Biologics (TSBX), Senti Biosciences (SNTI), Evaxion Biotech A/S (EVAX), Coeptis Therapeutics (COEP), and Brainstorm Cell Therapeutics (BCLI). These companies are all part of the "biological products, except diagnostic" industry. Silexion Therapeutics vs. Inhibikase Therapeutics IN8bio AIM ImmunoTech PharmaCyte Biotech NKGen Biotech Turnstone Biologics Senti Biosciences Evaxion Biotech A/S Coeptis Therapeutics Brainstorm Cell Therapeutics Silexion Therapeutics (NASDAQ:SLXN) and Inhibikase Therapeutics (NYSE:IKT) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, risk, dividends, community ranking, valuation, analyst recommendations, media sentiment, profitability and earnings. Does the media refer more to SLXN or IKT? In the previous week, Silexion Therapeutics and Silexion Therapeutics both had 4 articles in the media. Inhibikase Therapeutics' average media sentiment score of 0.88 beat Silexion Therapeutics' score of 0.28 indicating that Inhibikase Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Silexion Therapeutics 0 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Inhibikase Therapeutics 1 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do analysts rate SLXN or IKT? Silexion Therapeutics presently has a consensus price target of $1.00, indicating a potential upside of 212.11%. Inhibikase Therapeutics has a consensus price target of $6.50, indicating a potential upside of 223.38%. Given Inhibikase Therapeutics' higher possible upside, analysts clearly believe Inhibikase Therapeutics is more favorable than Silexion Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Silexion Therapeutics 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00Inhibikase Therapeutics 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00 Is SLXN or IKT more profitable? Silexion Therapeutics' return on equity of 0.00% beat Inhibikase Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Silexion TherapeuticsN/A N/A -249.43% Inhibikase Therapeutics N/A -350.63%-201.82% Does the MarketBeat Community believe in SLXN or IKT? Inhibikase Therapeutics received 8 more outperform votes than Silexion Therapeutics when rated by MarketBeat users. However, 100.00% of users gave Silexion Therapeutics an outperform vote while only 90.00% of users gave Inhibikase Therapeutics an outperform vote. CompanyUnderperformOutperformSilexion TherapeuticsOutperform Votes1100.00% Underperform VotesNo VotesInhibikase TherapeuticsOutperform Votes990.00% Underperform Votes110.00% Do institutionals and insiders believe in SLXN or IKT? 11.0% of Silexion Therapeutics shares are held by institutional investors. Comparatively, 3.8% of Inhibikase Therapeutics shares are held by institutional investors. 33.0% of Silexion Therapeutics shares are held by insiders. Comparatively, 14.7% of Inhibikase Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth. Which has more risk & volatility, SLXN or IKT? Silexion Therapeutics has a beta of -0.11, meaning that its stock price is 111% less volatile than the S&P 500. Comparatively, Inhibikase Therapeutics has a beta of 1.11, meaning that its stock price is 11% more volatile than the S&P 500. Which has stronger earnings & valuation, SLXN or IKT? Silexion Therapeutics has higher earnings, but lower revenue than Inhibikase Therapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioSilexion TherapeuticsN/AN/A$260KN/AN/AInhibikase Therapeutics$260K57.67-$19.03M-$2.67-0.75 SummaryInhibikase Therapeutics beats Silexion Therapeutics on 7 of the 12 factors compared between the two stocks. Ad DTIWhen it comes to NVDA… “acceleration cycles” are the keyExpert options trader Graham Lindman has been working on a new way to tap into Nvidia’s options… By simply isolating outsized “acceleration cycles” within Nvidia stock (most investors don’t even know it exists)... And thanks to many months and late nights working out the kinks of the systems… They have finally found a way to target these cycles on Nvidia over and over again.Use this link to see Nvidia Unchained right away! Get Silexion Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for SLXN and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart SLXN vs. The Competition Export to ExcelMetricSilexion TherapeuticsBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$4.43M$2.99B$5.09B$8.84BDividend YieldN/A1.91%5.04%4.07%P/E RatioN/A21.43101.4814.96Price / SalesN/A283.851,207.9887.23Price / Cash3.33169.3839.7136.27Price / Book-0.974.416.936.35Net Income$260,000.00-$41.63M$118.81M$225.93M7 Day Performance45.64%-4.38%-1.39%-0.03%1 Month Performance-4.61%-6.03%-3.29%2.00%1 Year PerformanceN/A26.38%32.29%27.82% Silexion Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)SLXNSilexion TherapeuticsN/A$0.32-3.0%$1.00+212.1%N/A$4.43MN/A0.00N/ANews CoverageGap DownIKTInhibikase Therapeutics2.7554 of 5 stars$2.01+1.5%$6.50+223.4%+130.1%$15.00M$260,000.000.008INABIN8bio2.7455 of 5 stars$0.32-0.5%$7.75+2,321.9%-62.8%$14.97MN/A0.0020AIMAIM ImmunoTech1.7806 of 5 stars$0.21+5.0%$3.00+1,317.1%-52.0%$13.49M$200,000.00-0.4520News CoverageHigh Trading VolumePMCBPharmaCyte Biotech0.6454 of 5 stars$1.75+1.7%N/A-21.1%$13.44MN/A2.732NKGNNKGen BiotechN/A$0.34+6.3%N/A-89.1%$11.94M$80,000.00-0.06N/AGap UpHigh Trading VolumeTSBXTurnstone Biologics3.2023 of 5 stars$0.47+2.1%$2.13+352.6%-84.8%$10.86M$19.31M0.0082SNTISenti Biosciences1.0759 of 5 stars$2.12flatN/A-42.1%$9.73M$2.56M-0.144News CoverageEVAXEvaxion Biotech A/S3.15 of 5 stars$1.37-2.1%$11.00+702.9%-81.7%$8.04M$70,000.000.0049COEPCoeptis TherapeuticsN/A$0.19flatN/A-83.3%$7.81M$80,000.00-0.652BCLIBrainstorm Cell Therapeutics4.4621 of 5 stars$1.24-1.6%$30.00+2,319.4%-53.4%$7.07MN/A-0.2640Analyst UpgradePositive News Related Companies and Tools Related Companies Inhibikase Therapeutics Alternatives IN8bio Alternatives AIM ImmunoTech Alternatives PharmaCyte Biotech Alternatives NKGen Biotech Alternatives Turnstone Biologics Alternatives Senti Biosciences Alternatives Evaxion Biotech A/S Alternatives Coeptis Therapeutics Alternatives Brainstorm Cell Therapeutics Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:SLXN) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredElon knows the truth, which is why they want him silencedElon Musk is one of mankind’s greatest innovators. But for all his visionary prowess and contributions to h...Porter & Company | Sponsored24/7 Automated Profits in CryptoThe 4th quarter of 2024 is shaping up to be one of the most explosive periods for crypto in recent memory. But...Crypto Swap Profits | SponsoredTrump Wins… But Elon Says Get Ready to BraceTrump's back in the White House, ready to hit the gas on America's comeback. He's taking on the economy wi...Genesis Gold Group | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Silexion Therapeutics Corp Please log in to your account or sign up in order to add this asset to your watchlist. Share Silexion Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
